RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析

◆英語タイトル:RegenxBio Inc (RGNX) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1343
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

RegenxBio Inc (RGNX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC, is a clinical-stage biotechnology company that discovers and develops gene therapy for the treatment of various retinal, metabolic, and neurodegenerative diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AAV vectors. RegenxBio employs its proprietary NAV technology platform, a gene delivery technology, to advance its product candidates. RegenxBio is headquartered in Rockville, Maryland, the US.

RegenxBio Inc Key Recent Developments

Apr 01,2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Feb 26,2020: REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
Jan 09,2020: REGENXBIO reports continued progress across programs in year-end 2019 corporate update
Nov 05,2019: REGENXBIO reports third quarter 2019 financial and operating results and recent operational highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
RegenxBio Inc – Key Facts
RegenxBio Inc – Key Employees
RegenxBio Inc – Key Employee Biographies
RegenxBio Inc – Major Products and Services
RegenxBio Inc – History
RegenxBio Inc – Company Statement
RegenxBio Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
RegenxBio Inc – Business Description
R&D Overview
RegenxBio Inc – Corporate Strategy
RegenxBio Inc – SWOT Analysis
SWOT Analysis – Overview
RegenxBio Inc – Strengths
RegenxBio Inc – Weaknesses
RegenxBio Inc – Opportunities
RegenxBio Inc – Threats
RegenxBio Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
RegenxBio Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 01, 2020: REGENXBIO and Ultragenyx announce new license agreement for use of NAV technology platform for the treatment of Rare Metabolic Disorder
Feb 26, 2020: REGENXBIO reports fourth quarter and full-year 2019 financial results and operational highlights
Jan 09, 2020: REGENXBIO reports continued progress across programs in year-end 2019 corporate update
Nov 05, 2019: REGENXBIO reports third quarter 2019 financial and operating results and recent operational highlights
Sep 30, 2019: REGENXBIO to present at The Chardan 3rd Annual Genetic Medicines Conference
Aug 07, 2019: REGENXBIO reports second quarter 2019 financial and operating results and additional positive interim phase I/IIa trial update for RGX-314 for the treatment of Wet AMD
Jul 24, 2019: REGENXBIO expands pipeline using NAV vectors to deliver therapeutic antibodies for the treatment of hereditary angioedema and neurodegenerative diseases
Jun 03, 2019: REGENXBIO selects Skyland PIMS as their process and product data management software system
May 15, 2019: REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies
May 07, 2019: REGENXBIO Reports First Quarter 2019 Financial and Operating Results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
RegenxBio Inc, Key Facts
RegenxBio Inc, Key Employees
RegenxBio Inc, Key Employee Biographies
RegenxBio Inc, Major Products and Services
RegenxBio Inc, History
RegenxBio Inc, Subsidiaries
RegenxBio Inc, Key Competitors
RegenxBio Inc, Ratios based on current share price
RegenxBio Inc, Annual Ratios
RegenxBio Inc, Annual Ratios (Cont...1)
RegenxBio Inc, Annual Ratios (Cont...2)
RegenxBio Inc, Interim Ratios
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
RegenxBio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
RegenxBio Inc, Performance Chart (2015 - 2019)
RegenxBio Inc, Ratio Charts
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
RegenxBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[RegenxBio Inc (RGNX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shionogi & Co Ltd (4507):製薬・医療:M&Aディール及び事業提携情報
    Summary Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing and marketing of pharmaceutical products, diagnostic reagents and medical devices. The company's core pharmaceuticals product business offers drugs for the treatment of disorders in the areas of metabolism, infe …
  • Burns & McDonnell:企業の戦略・SWOT・財務情報
    Burns & McDonnell - Strategy, SWOT and Corporate Finance Report Summary Burns & McDonnell - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Evofem Biosciences Inc (EVFM):製薬・医療:M&Aディール及び事業提携情報
    Summary Evofem Biosciences Inc (Evofem) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes reproductive and contraceptive care products for women. The company’s lead product candidate includes Amphora, a non-hormonal vaginal contraceptive gel for the prevention …
  • Oldenburgische Landesbank AG:企業の戦略・SWOT・財務分析
    Oldenburgische Landesbank AG - Strategy, SWOT and Corporate Finance Report Summary Oldenburgische Landesbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • CP All Public Company Ltd (CPALL):企業の財務・戦略的SWOT分析
    CP All Public Company Ltd (CPALL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Bouwinvest Real Estate Investment Management B.V.:企業の戦略・SWOT・財務情報
    Bouwinvest Real Estate Investment Management B.V. - Strategy, SWOT and Corporate Finance Report Summary Bouwinvest Real Estate Investment Management B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structur …
  • AzurRx BioPharma Inc (AZRX):製薬・医療:M&Aディール及び事業提携情報
    Summary AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that research and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company’s products under development include MS1819, a non-systemic yeast recombinant …
  • Kotra Industries Berhad (KOTRA):企業の財務・戦略的SWOT分析
    Kotra Industries Berhad (KOTRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Bemis Company Inc (BMS):企業の財務・戦略的SWOT分析
    Bemis Company Inc (BMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Midatech Pharma US Inc:企業の戦略的SWOT分析
    Midatech Pharma US Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • AF AB (AF B)-エネルギー分野:企業M&A・提携分析
    Summary AF AB is an engineering and consulting company. It offers various services such as product development and IT support to sectors including automotive, telecom, defense and life sciences. The company also provides services such as communications systems management, development of customized b …
  • Thales SA:企業のM&A・事業提携・投資動向
    Thales SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Thales SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Bioplus Life Sciences Private Limited:企業の戦略・SWOT・財務情報
    Bioplus Life Sciences Private Limited - Strategy, SWOT and Corporate Finance Report Summary Bioplus Life Sciences Private Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Bank of Nanjing Co., Ltd.:戦略・SWOT・企業財務分析
    Bank of Nanjing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Nanjing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Franz Haniel & Cie. GmbH:企業の戦略・SWOT・財務分析
    Franz Haniel & Cie. GmbH - Strategy, SWOT and Corporate Finance Report Summary Franz Haniel & Cie. GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • HPQ Silicon Resources Inc (HPQ):企業の財務・戦略的SWOT分析
    Summary HPQ Silicon Resources Inc (HPQ Silicon), formerly Uragold Bay Resources, is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, production and development of silicon, gold and quartz properties, among others. It holds interests in The B …
  • Banco BPI SA:企業の戦略・SWOT・財務分析
    Banco BPI SA - Strategy, SWOT and Corporate Finance Report Summary Banco BPI SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Morinaga & Co., Ltd. (2201):企業の財務・戦略的SWOT分析
    Morinaga & Co., Ltd. (2201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • PG&E Corp:企業の発電所・SWOT分析2018
    PG&E Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executiv …
  • 21st Century Oncology Inc:企業の戦略的SWOT分析
    21st Century Oncology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆